CoChat

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Open access

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background HannaH (NCT00950300) was a phase III, randomized, international, open-label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations [subcutaneous (s.c.) and intravenous (i.v.)] in HER2-positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting. The co-primary end points, to show noninferiority of s.c. versus i.v. trastuzumab in terms of serum concentration (Ctrough) and pathologic complete response (pCR) were met; safety profiles were comparable at 12 months' median follow-up. Secondary end points included safety and tolerability, PK profile, immunogenicity, and event-free survival (EFS). We now report updated safety and efficacy data after a median follow-up of 20 months.Patients and methods Patients (N = 596) were treated with eight cycles of neoadjuvant chemotherapy, administered concurrently with 3-weekly s.c. trastuzumab (fixed dose of 600 mg) or the standard weight-based i.v. method. Following surgery, patients continued trastuzumab treatment to complete 1 year of therapy. Updated analyses of PK, efficacy, safety, and immunogenicity data were carried out.Results s.c. trastuzumab was generally well tolerated and the incidence of adverse events (AEs), including grade 3 or 4 AEs, between treatment groups was comparable. A slightly higher incidence of serious AEs (SAEs), mainly due to infections, was reported with s.c. treatment {64 [21.5%; 95% confidence interval (CI) 17.0%-26.7%] versus 42 (14.1%; 95% CI 10.4%-18.6%) in the i.v. group}; however, the differences were small and often based on rare events, with no observable pattern across reported events. An early analysis of EFS showed rates of 95% in both groups 1 year postrandomization. Exploratory analyses did not reveal an association between toxicity and body weight or exposure.Conclusions Overall, the safety profile of s.c. trastuzumab was consistent with the previously published data from HannaH and the known safety profile of i.v. trastuzumab. EFS rates were comparable between the i.v. and s.c. groups.Clinical trial number NCT00950300.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdu524

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 1

  1. Haller, 2007, Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase, Pharm Tech, 10, 861

Cited by

See all 114

Metadata

Authors
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., & Ismael, G.
Affiliations
  • Sana Klinikum Offenbach (DE)
  • Asan Medical Center (KR)
  • Palacký University Olomouc (CZ)
  • Centre Hospitalier Universitaire de Besançon (FR)
  • F. Hoffmann-La Roche AG (CH)
  • Moscow City Oncology Hospital №62 (RU)
  • Genentech (US)
  • Hospital Amaral Carvalho (BR)
Corresponding author
Jackisch, C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2015-02
Volume
26
Issue
2
Pages
320-325
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2115527794
Cited by
114
References
10
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 17 · 2018: 20 · 2017: 11 · 2016: 12 · 2015: 12
FWCI
5.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Javna Agencija za Raziskovalno Dejavnost RS
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
trastuzumab, subcutaneous administration, intravenous administration, HER2-positive breast cancer, neoadjuvant therapy, adjuvant therapy, pathological complete response, pharmacokinetics, immunogenicity, adverse events, event-free survival, body weight, drug exposure, locally advanced breast cancer, inflammatory breast cancer, non-inferiority, infection, weight-based dosing
MeSH terms
Trastuzumab, Adult, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Middle Aged, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. https://app.cochat.ai/papers/10.1093/annonc/mdu524
The paper
Jackisch, C., Kim, S.-B., Semiglazov, V., Melichar, B., Pivot, X., Hillenbach, C., Stroyakovskiy, D., Lum, B. L., Elliott, R., Weber, H. A., & Ismael, G. (2015). Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Annals of Oncology. https://doi.org/10.1093/annonc/mdu524

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.